Live Vaccines and Innate Immune Training in COPD. (NCT06257212) | Clinical Trial Compass
CompletedPhase 4
Live Vaccines and Innate Immune Training in COPD.
Denmark60 participantsStarted 2024-02-28
Plain-language summary
A randomized, single-blinded clinical pilot study to assess whether vaccination with live attenuated vaccines can induce trained immunity and cause beneficial changes in patients with COPD.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Specialist verified and spirometry-confirmed COPD
* Age \> 40 years.
* Negative HIV-test.
* Able to give informed consent.
Exclusion Criteria:
* Acute febrile illness.
* Known allergy to BCG or MMR vaccines or serious adverse effects at previous vaccination.
* Allergy to MMR vaccine components, neomycin, or egg proteins.
* Known prior, active, or latent infection with mycobacterium tuberculosis.
* Pregnancy or breastfeeding.
* Vaccination with a live vaccine within the last 4 weeks.
* Being severely immunocompromised (HIV-1 infection, organ- or bone marrow transplantation, chemotherapy, primary immune defect, anti-cytokine therapy, immunosuppressant treatment).
* Oral or intravenous corticosteroid at dose of ≥10 mg/day with duration over 3 months.
* Active solid or non-solid malignancy or lymphoma, excluding basal cell carcinoma within 2 years.
* Treatment with immunoglobulins within the last 3 months or expected treatment with immunoglobulins for the duration of the trial.
What they're measuring
1
Innate immune training.
Timeframe: From inclusion to 4 months post-inclusion.